Drug Profile
Research programme: cancer therapeutics - Cotinga Pharmaceuticals
Alternative Names: COTI-04; COTI-219; COTI-4A; COTI-58Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Critical Outcome Technologies
- Developer Cotinga Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; Cyclin-dependent kinase modulators; Iron chelating agents; KRAS protein inhibitors; Methylenetetrahydrofolate reductase modulators; P53 gene modulators; Proto oncogene protein c-akt inhibitors; Thymidylate synthase expression modulators; Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Colorectal cancer; Small cell lung cancer
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for preclinical development in Cancer in Canada (PO)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in Canada (PO)
- 28 Jan 2020 No recent reports of development identified for research development in Colorectal-cancer in Canada (PO)